# Nuclide record donafenib (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/donafenib/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "donafenib" ;
  schema:name "Donafenib"@en ;
  schema:description "Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option."@en ;
  schema:url <https://nuclide.cc/drugs/donafenib/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Donafenib> ;
  schema:citation <https://www.zelgen.com/en/>, <https://doi.org/10.1200/JCO.20.02672>, <https://www.nmpa.gov.cn> ;
  nuclide:status "approved" ;
  nuclide:tag "china" ;
  nuclide:modality "Small-molecule multi-kinase inhibitor (deuterated sorafenib)" ;
  schema:alternateName "Zepsun" ;
  nuclide:approval "China 2021: First-line unresectable hepatocellular carcinoma (ZGDH3)", "China 2022: Radioiodine-refractory differentiated thyroid cancer" ;
  nuclide:indications <https://nuclide.cc/indications/hcc/>, <https://nuclide.cc/indications/thyroid/> .